

APOC3 Rabbit pAb

Catalog # AP96884

Product Information

Application	WB
Primary Accession	P06759
Other Accession	P06759
Reactivity	Rat, Mouse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	11117
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from rat Apolipoprotein CIII
Epitope Specificity	41-80/101
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Belongs to the apolipoprotein C3 family.
Post-translational modifications	O-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan.
DISEASE	Hyperalphalipoproteinemia 2 (HALP2) [MIM:614028]: A condition characterized by high levels of high density lipoprotein (HDL) and increased HDL cholesterol levels. Note=The disease is caused by mutations affecting the gene represented in this entry.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. It inhibits lipoprotein lipase and hepatic lipase and it is thought to delay catabolism of triglyceride-rich particles. An increase in apoC-III levels induces the development of hypertriglyceridemia.

Additional Information

Other Names	APOCIII; Apo-C3; ApoC-3; apo-CIII; apoC-III; APOC3_HUMAN; APOC3; Apolipoprotein C3; APOC3_MOUSE; APOC3_RAT; apolipoprotein C-III
Dilution	WB=1:500-2000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	Apoc3
Function	Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners.
Cellular Location	Secreted {ECO:0000250 UniProtKB:P02656}.
Tissue Location	Synthesized predominantly in liver and to a lesser degree in intestine.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.